Considerations for management of patients with diabetes mellitus and acute COVID-19  

作　　者：Efterpi Mougakou Maria Kyziroglou Alexandra Tsankof Evangelos Cholongitas Konstantinos Tziomalos 

机构地区：[1]First Department of Internal Medicine,Medical School,National and Kapodistrian University of Athens,Laiko General Hospital,Athens 11527,Greece [2]First Propedeutic Department of Internal Medicine,Medical School,Aristotle University of Thessaloniki,AHEPA Hospital,Thessaloniki 54636,Greece

出　　处：《World Journal of Diabetes》2022年第10期802-808,共7页世界糖尿病杂志（英文版）（电子版）

摘　　要：Diabetes mellitus(DM)is an independent risk factor for admission to intensive care unit and death in patients with coronavirus disease 2019(COVID-19).On the other hand,medications used in the management of COVID-19 are potentially associated with increases in blood glucose levels and a higher incidence of infections.Accordingly,care of patients with DM and acute COVID-19 requires careful consideration of both diseases.Hyperglycemia and hypoglycemia are associated with adverse outcomes and therefore frequent measurement of blood glucose levels and a basal-bolus insulin regimen are required in most patients.Regarding the management of COVID-19,dexamethasone increases blood glucose levels and might also increase the risk for infections.On the other hand,limited data suggest that antiviral and immunomodulatory agents used in COVID-19 are not strongly associated with higher incidence of infections in this population.As knowledge evolves in this field,optimization of the management of both DM and COVID-19 will hopefully improve the outcome of these patients。

关 键 词：Diabetes mellitus COVID-19 INSULIN Antidiabetic agents DEXAMETHASONE TOCILIZUMAB Remdesivir 

分 类 号：R563.1[医药卫生—呼吸系统] R587.2[医药卫生—内科学]